180 related articles for article (PubMed ID: 34626691)
1. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
Huang KB; Pan YH; Shu GN; Yao HH; Liu X; Zhou M; Wei JH; Chen ZH; Lu J; Feng ZH; Chen W; Han H; Zheng ZS; Luo JH; Zhang JX
Cancer Lett; 2021 Dec; 523():121-134. PubMed ID: 34626691
[TBL] [Abstract][Full Text] [Related]
2. Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis.
Li W; Li G; Cao L
Bioengineered; 2022 Apr; 13(4):9729-9740. PubMed ID: 35412955
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
[TBL] [Abstract][Full Text] [Related]
4. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
8. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
9. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
[TBL] [Abstract][Full Text] [Related]
10. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
11. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis.
Wang Q; Gao S; Shou Y; Jia Y; Wei Z; Liu Y; Shi J; Miao D; Miao Q; Zhao C; Liu C; Yang H; Xu T; Zhang X
Int J Biol Sci; 2023; 19(4):1266-1283. PubMed ID: 36923928
[TBL] [Abstract][Full Text] [Related]
12. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair.
Tan L; Huang Z; Chen Z; Chen S; Ye Y; Chen T; Chen Z
J Chemother; 2023 Feb; 35(1):11-18. PubMed ID: 34927575
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway.
Li L; Zhao S; Liu Z; Zhang N; Pang S; Liu J; Liu C; Fan Y
Cell Death Dis; 2021 Feb; 12(2):220. PubMed ID: 33637706
[TBL] [Abstract][Full Text] [Related]
14. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C; Perez-Gracia JL; Garcia-Donas J; Rodriguez-Antona C; Guruceaga E; Esteban E; Suarez C; Castellano D; del Alba AG; Lozano MD; Carles J; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Gurpide A; Lopez-Picazo JM; Hernandez AG; Mellado B; Martínez E; Moreno F; Font A; Calvo A
PLoS One; 2014; 9(1):e86263. PubMed ID: 24475095
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma.
Adelaiye-Ogala R; Damayanti NP; Orillion AR; Arisa S; Chintala S; Titus MA; Kao C; Pili R
Cancer Res; 2018 Jun; 78(11):2886-2896. PubMed ID: 29572225
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma.
Xing Q; Li R; Xu A; Qin Z; Tang J; Zhang L; Tang M; Han P; Wang W; Qin C; Du M; Zhang W
Cancer Med; 2019 Jun; 8(6):2886-2896. PubMed ID: 31038847
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
Pan Y; Lu X; Shu G; Cen J; Lu J; Zhou M; Huang K; Dong J; Li J; Lin H; Song H; Xu Q; Han H; Chen Z; Chen W; Luo J; Wei J; Zhang J
Cancer Res; 2023 Jan; 83(1):103-116. PubMed ID: 36264173
[TBL] [Abstract][Full Text] [Related]
18. circPTPN12 promotes the progression and sunitinib resistance of renal cancer via hnRNPM/IL-6/STAT3 pathway.
Shou Y; Yue C; Wang Q; Liu J; Xu J; Miao Q; Liu D; Yang H; Liu Y; Zhang X
Cell Death Dis; 2023 Mar; 14(3):232. PubMed ID: 37002206
[TBL] [Abstract][Full Text] [Related]
19. CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1.
Zhang MX; Wang JL; Mo CQ; Mao XP; Feng ZH; Li JY; Lin HS; Song HD; Xu QH; Wang YH; Lu J; Wei JH; Han H; Chen W; Mao HP; Luo JH; Chen ZH
Oncogene; 2022 Aug; 41(33):3979-3990. PubMed ID: 35798876
[TBL] [Abstract][Full Text] [Related]
20. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]